ProteqFlu

RSS

Equine influenza vaccine (live recombinant)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 21/08/2020

Authorisation details

Product details
Name
ProteqFlu
Agency product number
EMEA/V/C/000073
Active substance
Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus
International non-proprietary name (INN) or common name
Equine influenza vaccine (live recombinant)
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI05AD02
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
06/03/2003
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Product information

29/07/2020 ProteqFlu - EMEA/V/C/000073 - IG/1264

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals
  • Live viral vaccines equine influenza virus

Therapeutic indication

Active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.

Assessment history

How useful was this page?

Add your rating